Immunology / Virology & Vaccines

#Covid-19 #Immunology / Virology & Vaccines #Research study #Vaccines

Is this the solution to increasing Covid-19 vaccine uptake?

The largest ever study of Covid-19 vaccine messaging shows that emphasising the personal benefits rather than collective of vaccination may be the most effective way to persuade people who are sceptical. Researchers from the University of Oxford, funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre… Read More

#Covid-19 #News #Trending News

#Covid-19 #Drug delivery #Immunology / Virology & Vaccines #Moderna #Vaccines

500 million Covid-19 vaccine doses delivered to lowest income countries

Moderna has announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of the Covid-19 Vaccine Moderna, including an initial 34 million doses to be delivered in the fourth quarter of 2021. Through this agreement, on behalf of the COVAX Facility, Gavi also retains… Read More

#Covid-19 #News

#Anti-viral drug screening #Assay validation #Automated workflows #Drug screening #High throughput screening #Immunology / Virology & Vaccines #Microplate readers #SARS-CoV-2

Covid targets in the crosshairs: Arctoris’ Ulysses platform case studies

Covid-19 has highlighted the current operational vulnerabilities in pharmaceutical research and in the drug discovery pipeline. Bringing new drugs to the market is still a slow and expensive process, with far too high costs, failure rates and cycle times. With low reproducibility and inefficient processes delaying the path to approval,… Read More

#Editor's Choice #News

#Antigen #Drug discovery #Immunology / Virology & Vaccines #Monoclonal antibodies

How to get your drug to market faster

The pressure to take your drug to market faster is increasing. To achieve a successful journey to the first clinical trial phase in the fastest time possible, Eppendorf has identified three key elements that it is addressing in an eBook.  Comply with audit requirements and relevant certifications  Drive process efficiencies… Read More

#Editor's Choice #News

#Biotechnology #Cell and gene therapy #Covid-19 #Drug delivery #Drug development #Drug technology #Immunology / Virology & Vaccines

Antibody therapeutics: the other race for immunity against SARS-CoV2

Sophie Lutter, OXGENE, looks at the important role antibody therapeutics have to play and how, as the world has looked for Covid-19 treatments in the last year, their significance has been noted. As the world continues to adjust and respond to the impact of the Covid-19 pandemic, the race to… Read More

#Covid-19 #Exclusive Content #News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA #Vaccines

Moderna invests to increase global supply for Covid-19 vaccine

Moderna is to increase supply at its manufacturing facilities, which it expects will increase global 2022 capacity to up to 3 billion doses of its Covid-19 vaccine. This will depend upon the mix between the authorised Moderna Covid-19 vaccine at the 100 μg dose level and potentially lower… Read More

#News

#Biopharmaceuticals #Covid-19 #Drug delivery #Drug development #Drug discovery #Drug innovation #Immunology / Virology & Vaccines #Pharma #Pharmaceuticals #Vaccines

Integration at its best: Dalton Pharma outlines its CDMO expertise

Dalton Pharma Services, a contract development and manufacturing organisation (CDMO) offers expertise in drug discovery, formulation and process development, custom synthesis, and GMP manufacturing services. Lu Rahman spoke to CEO, Peter Pekos about the company’s ongoing expertise. LR: The company has experience supplying the needs of the orphan drug field… Read More

#Exclusive Content #News #Opinion

#Covid-19 #Immunology / Virology & Vaccines #Research #Vaccines

Covid-19 vaccine responses to be studied in people with immune deficits

A study assessing how people with immune system deficiencies or dysregulations respond to Covid-19 vaccination has begun enrolling participants at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. The single-site study is led by researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and aims… Read More

#News

#Assay #Assay development optimisation & technology #Covid-19 #Drug development #Immunology / Virology & Vaccines #Reagents

The Native Antigen Company launches assay development kit

The Native Antigen Company has announced the launch of its SARS-CoV-2 Neutralisation Assay Development Kit. The kit can be used to identify and qualitatively assess the ability of antibodies to neutralise SARS-CoV-2-receptor binding, to support research into variants and their effects on natural and vaccine-induced patient immunity. The kit contains… Read More

#News

Mosquito
#Clinical trial #Immunology / Virology & Vaccines #Malaria #Research #Vaccines

Malaria vaccine first to achieve WHO-specified 75% efficacy goal

Researchers from the University of Oxford and their partners have reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up. In their findings (posted on SSRN/Preprints with The Lancet), they note that they are the first to… Read More

#News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #mRNA #Pfizer #Vaccines

Evonik delivers first lipids to BioNTech ahead of schedule

Chemical specialist Evonik is helping to accelerate the production of the Covid-19 vaccine from Pfizer-BioNTech by suppling an essential component. Evonik is delivering first batches of urgently needed lipids for the mRNA-based vaccine to BioNTech months earlier than anticipated. Specialists at Evonik’s Hanau site set up the lipid production in… Read More

#Covid-19 #News

#Biologics #Covid-19 #Drug delivery #Gene therapy #Genetics / genomes #Immunology / Virology & Vaccines #RNA

The challenge of providing rapid, effective protection against Covid-19

Lisa Osborne, CEO at RANA Healthcare Solutions interviews Daniel Kavanagh, PhD, Senior Scientific Advisor, Gene Therapy at WCG. The Covid-19 pandemic has put vaccine development centre-stage. Never have citizens around the world been so focused on the length of time it takes to develop, test, approve, manufacture and distribute new… Read More

#Covid-19 #Exclusive Content #News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Vaccine candidate #Vaccines

Novavax to participate study comparing mixed Covid-19 vaccines 

Novavax has announced its participation in a newly expanded investigator-initiated Phase II clinical trial called Comparing Covid-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2), to be conducted by the University of Oxford and supported by the UK Vaccines Taskforce. Novavax’ recombinant protein vaccine candidate, NVX-CoV2373, is one of four Covid-19… Read More

#Covid-19 #News

#Antibodies #Clinical trial #Covid-19 #Immunology / Virology & Vaccines

Trial begins of antibody to treat Covid-19 respiratory disease

A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalised with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes Covid-19, has begun. The Phase II trial, called the Covid-19 anti-CD14 Treatment Trial (CaTT), is… Read More

#Covid-19 #News

#Clinical trial #Covid-19 #Drug development #Immunology / Virology & Vaccines #Research #Vaccines

NIH begins study of allergic reactions to Covid-19 vaccines

A clinical trial is underway to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech Covid-19 vaccines. A systemic allergic reaction to a vaccine occurs in one or more parts of… Read More

#Covid-19 #News